Viyash Scientific Limited submitted its Q2 FY27 investor presentation pursuant to Regulation 30 of SEBI Listing Regulations. The document contains financial results for Q2 and H1 FY27 along with business updates and strategic initiatives.

Financial Performance

Q2 FY27 Results (₹ Mn):

  • Revenue from Operations: ₹9,879 (up 16.2% YoY from ₹8,503)
  • Gross Margin: ₹5,305 (53.7% of revenue)
  • EBITDA: ₹2,077 (21.0% of revenue)
  • Earnings Before Tax: ₹1,177 (11.9% of revenue)
  • Earnings After Tax: ₹847 (up 16.1% YoY from ₹729)
  • ESOP Cost: ₹421 (significantly higher due to incremental ESOP grants pursuant to scheme of amalgamation)
  • Taxes: ₹330

H1 FY27 Results (₹ Mn):

  • Revenue from Operations: ₹19,343 (up 17.8% YoY from ₹16,419)
  • EBITDA: ₹4,124 (up 29.9% YoY from ₹3,176)
  • Earnings After Tax: ₹1,639 (up 49.4% YoY from ₹1,098)
  • Adjusted PAT with normalized ESOP cost: ₹2,040

Business Segment Performance

Revenue Distribution Q2 FY27 (₹ Mn):

  • Formulations: ₹5,587 (up 19% YoY)
  • Europe: ₹1,864 (up 22% YoY)
  • Emerging Markets: ₹2,030 (up 39% YoY)
  • India: ₹504 (up 39% YoY)
  • USA: ₹1,189 (down 11% YoY)
  • APIs: ₹4,154 (up 12% YoY)
  • Other Sales: ₹118
  • Global Sales: ₹9,859 (up 16% YoY)
  • Ind AS 29 Adjustment (hyperinflation in Turkey): ₹21

Strategic Developments

Acquisition Completion:

  • Completed acquisition of BioForLife in Italy on October 1, 2026
  • Execution of SPA: July 21, 2026
  • Provides access to Italian companion animal market with 85-90 products
  • Sales force has 85% vet clinic coverage in Italy

Capacity Expansion:

  • Adding 128 KL additional API capacity to meet rising demand
  • All necessary approvals received for new block
  • Investing in new oncology capabilities including OEB 4 & 5 high-potent containment
  • Building end-to-end oncology platform from API to finished dosage
  • Developing in-house manufacturing facility for companion animal pipeline

Operational Highlights

  • 16 world-class manufacturing facilities
  • 335+ scientists across R&D centers
  • 190+ patents filed
  • 1,000+ registrations globally
  • Operations in 150+ countries with 250+ global customers

Management Commentary

Dr. Hari Babu Bodepudi, Managing Director and Group CEO, stated: "Viyash Scientific has delivered yet another stellar quarter with H1 revenue up 17.8% and H1 profit after tax (PAT) at INR 164 Cr, up ~50% from last year. Our focus remains on disciplined execution, R&D-led growth and sustainable value creation for customers and stakeholders."

Awards & Recognition

  • Best ESG Performance Award (National Awards for Excellence)
  • CSR Excellence in Healthcare & Community Development (National Awards for Excellence)

Board of Directors

Listed board members include Dr. Kamal Sharma (Chairman), Dr. Haribabu Bodepudi (MD & Group CEO), Mr. Abhiroop Jayanthi, Mr. Rajaram Narayanan, Mr. Milind Sarwate, Mr. Anuj Poddar, Mr. Amit Jain, and Ms. Revati Kasture.